Contact

The CDMO made to make cell therapies mainstream.

Full-spectrum manufacturing services and pre-established platforms enabling drug developers to deliver scalable immune-oncology and regenerative medicine cell therapies faster and with commercially viable cost structures

cellistic-lab-scientist-accent-graphic-1_5

Pursuing an immune oncology or cell regenerative medicine cell therapy? Start here.

As the global leader in allogeneic iPSC-derived cell therapy manufacturing, we offer established cell line development, process development, GMP manufacturing platforms, ready-to-use iPSC lines, and proprietary gene-editing capabilities.

Which means Cellistic is ready right now to help you identify and accelerate your highest-value opportunities — especially if you’re looking to serve a much larger market than is possible with an autologous or donor-derived allogeneic approach.

If you’ve got a breakthrough idea

we can guide you step-by-step through every part of development and manufacturing.

If you need tech transfer

we have the processes and analytical methods in place – and the experience on-hand – to optimize or scale to your exact specifications.

If you’re looking for a CDMO to develop or optimize your manufacturing process

our pre-established platforms and enabling technologies offer an efficient, proven way to maintain your momentum.
Entry point diagram v2-1
Artboard 1 1

Talk to the cell therapy CDMO.

See how Cellistic can remove the scientific, operational, and economic barriers to scalable patient delivery. And, over time, help ensure the use of extraordinary therapies becomes a very ordinary thing.

Artboard 1 1

The CDMO that can take your cell therapy mainstream.

Cellistic integrates the services, platforms, and expertise required to enable successful iPSC-derived allogeneic cell therapy GMP manufacturing – and we’re continually expanding our capabilities with a single purpose in mind: to help you limit risk, accelerate time to clinic, and reduce costs.


Puzzle Icon

Platforms + Technologies

Exclusive Pulse™ Platform for iPSC cell line development and Echo Platform for scalable GMP manufacturing that put your program on a faster track

Vials Icon

CDMO  Services

Full-spectrum services tuned to your program’s distinct needs and deployed to streamline its progress

Cell Types Icon

Cell Types 

Broad, deep expertise in (iPSC-derived) cell types that removes the uncertainties of harnessing their full potential

We are here: The point of Cellistic’s difference.

Cellistic’s unique advantage sits squarely at the intersection of focus, platforms and expertise. Other cell therapy manufacturers or in-house teams may be able to deliver some of these benefits, but only Cellistic can deliver on all three.

Working_Icons-2

Focus

Since day one, we’ve maintained a singular focus on iPSCs. So every investment in technology and every expansion of our experience  goes directly to strengthening our core to your benefit.

Turn the promise of your program into a reality.

Whether you’re pursuing an autologous cell therapy or already have an iPSC-based project underway, Cellistic offers a practical and proven path forward for your cell therapy or regenerative medicine — making it possible to turn a high-potential idea into a viable therapeutic faster and more efficiently.

Group 35264
iPSC-Derived Allogeneic Autologous Donor-Derived Allogeneic
Your opportunity

Transfer an existing process to a flexible, full-scale, iPSC-focused CDMO

Go from one-to-one to one-to-many using our proven platforms

Overcome limitations to increase scale, consistency, quality, and characterization

Purpose-built to deliver on iPSC potential.

Our headquarters in Mont-Saint-Guibert, Belgium, is home to the first EMA-certified and FDA and PMDA compliant purpose-built iPSC cell therapy GMP manufacturing facility.

With all capabilities in a single location, our clients collaborate closely with our multidisciplinary team, with everyone aligned on the shared goal: developing and manufacturing iPSC-based allogeneic cell therapies as efficiently and cost-effectively as possible.

lab-collection

How can we help propel your cell therapy?

Let’s start with what’s on your mind – your project plans, your questions about iPSC technology, your most pressing scientific and business drivers. We’re here to listen and, if we’re a good fit, to help you maximize the opportunity and value of your cell therapy.